What is this guy smoking? Raises PT to $20 despite saying no other bidders are in sight?
Cowen analyst Ritu Baral maintained an Outperform rating on Avanir Pharmaceuticals (NASDAQ:AVNR) with a $20 price target, following the news that the company has entered into a definitive agreement with Otsuka Pharmaceutical pursuant to which Otsuka will acquire Avanir for $17.00 per share in cash.
Baral observed, “We see this as an underwhelming offer but see no evidence of other bidders before the tender offer begins in 10 business days and the close of the transaction in 1Q15.
The Thought Police: To censor and protect. Craig Bruce
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.